Toft Group Executive Search has placed Paul Shin as Vice President of Clinical Operations for Intercept Pharmaceuticals in San Diego, California. Mr. Shin was most recently Global Head of R&D Operations at Nestle Health Science. Previously, he worked with Avanir Pharmaceuticals as Vice President, Research & Development Operations, Sr. Director, Clinical Operations & Pharmacovigilance at Spectrum Pharmaceuticals, and Director, Clinical Operations & Medical Affairs at Prometheus Therapeutics & Diagnostics. Earlier in his industry career, Mr. Shin supported clinical operations for Valeant Pharmaceuticals and MDS Pharma Services.
Mr. Shin holds a B.S. in Psychobiology from the University of California, Riverside.
About Toft Group Executive Search
Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide. The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.
About Intercept Pharmaceuticals
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.